Protective and pathogenic antibody responses from a primate Shigella outbreak inform vaccine design
Gallant, R. M.; Savarino, P.; Pulido, S.; Gilman, M. S. A.; Lu, T.; Hayes, J. M.; Xerri, N. L.; Williams, T.; Ochoa, M. A.; Dietz, Z.; Peterson, E.; Scott, T. A.; Hartmann, F.; Baker, S. G.; Kaminski, R. W.; Sok, D.; Kruse, A. C.; Picking, W.; Capuano, S. V.; Schmidt, H. R.
Show abstract
There is currently no approved vaccine for Shigella spp., a leading cause of diarrhea that are increasingly resistant to antimicrobials. Shigella vaccine development is complicated in part by an incomplete understanding of the structural and molecular determinants of immunity. To address this, we isolated monoclonal antibodies (mAbs) against candidate Shigella vaccine antigens using samples from a Shigella flexneri outbreak in a non-human primate (NHP) research facility. We found that antibodies targeting the Shigella O-antigen (O-Ag) can undergo significant affinity maturation (>10%) to acquire broad cross-reactivity across S. flexneri serotypes. We also found that the virulence-associated type III secretion system (T3SS) proteins IpaD and IpaB elicit moderate T cell and robust antibody responses. T3SS antibodies either inhibit, or - surprisingly - enhance bacterial virulence in vitro and in vivo depending on their epitope specificity. These findings provide key insights into protective and deleterious immune responses against Shigella that directly inform vaccine immunogen design.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Crimean-Congo Hemorrhagic Fever Survivors Elicit Protective Non-Neutralizing Antibodies that Target 11 Overlapping Regions on Viral Glycoprotein GP38 97%
- Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals 96%
- Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple epitopes 95%
Similar papers in this journal
- Analysis of the Diverse Antigenic Landscape of the Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype 96%
- Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5 95%
- Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals 95%
Similar papers in this journal
- citrOgen: a synthesis-free polysaccharide and protein antigen-presentation to antibody-induction platform 96%
- Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients 95%
- Immunologic and Biophysical Features of the BNT162b2 JN.1- and KP.2-Adapted COVID-19 Vaccines 95%
Similar papers in this journal
- High-affinity, neutralizing antibodies to SARS-CoV-2 can be made in the absence of T follicular helper cells 94%
- CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals 94%
- Mucosal immunity against SARS-CoV-2 variants of concern including Omicron following vaccination 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.